Propofol shortage resolved; Genzyme gets familiar face as new CEO;

> Hospira ($HSP) and APP Pharma ($APPX) report that the propofol drug shortage has been resolved. FDA listing

> Sanofi ($SNY) has announced the appointment of David Meeker as CEO of the Genzyme unit, effective November 1; Meeker is currently Genzyme's COO. Sanofi CEO Christopher Viehbacher (photo) will remain Genzyme chairman. Release

> Regulatory pressure and a more detailed understanding of costs will push drugmakers to change their minds about outsourcing and take back control of APIs and components. Article (sub. req.)

> The New Jersey Department of Labor and Workforce Development has made available $3.6 million in federal funding for retraining and re-employment opportunities for laid-off pharma workers. Story

> Contract manufacturer Patheon ($PTI) has won two contracts, worth $18 million, to make experimental Type 2 diabetes drugs for Boehringer Ingelheim. News

> Lonza (LONN:VX) has formed Lonza Microbial Control after completing the acquisition of Arch Chemicals. Story

> In a Pharma IQ survey, 57% of respondents report that migrating single-use systems from development into a commercial state is a main goal. Item

> The future for aseptic operations is isolated robotics. Column

> Almac says it will expand its pharma development services with a new facility in Craigavon, Ireland. Release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.